Anti-Hu CD25 PE-CyTM5

CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor (IL2R) . Together with beta and gamma subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.

Human

PHA-activated peripheral blood leucocytes

CD25

MEM-181

FC (QC tested)

PE-Cy

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

*Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May;19 (5) :675-84., URL: http://www.ncbi.nlm.nih.gov/pubmed/17446208?itool=, *Černý V, Hrdý J, Novotná O, Petrásková P, Boráková K, Kolářová L, Prokešová L: Distinct characteristics of Tregs of newborns of healthy and allergic mothers. PLoS One. 2018 Nov 26;13 (11) :e0207998., URL: https://www.ncbi.nlm.nih.gov/pubmed/30475891 , *Černý V, Novotná O, Petrásková P Hudcová K, Boráková K, Prokešová L, Kolářová L, Hrdý J: Lower functional and proportional characteristics of cord blood treg of male newborns compared with female newborns. Biomedicines 2021, 9, 170., URL: https://pubmed.ncbi.nlm.nih.gov/33572097/

*Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct;28 (10) :1319-25., URL: https://www.ncbi.nlm.nih.gov/pubmed/15371947?ordin, *Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14., URL: https://www.ncbi.nlm.nih.gov/pubmed/11053100?ordin, *Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75) . Res Immunol. 1992 Jan;143 (1) :33-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/1565844?ordina, *Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro. Pathology. 1991 Jul;23 (3) :224-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/1838146?ordina

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The antibody MEM-181 reacts with an extracellular epitope of CD25 (Interleukin-2 receptor alpha chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells) ; it is lost on resting B and T lymphocytes.

6

Mouse IgG1 kappa